Related references
Note: Only part of the references are listed.Characterizing CDK12-Mutated Prostate Cancers
Pasquale Rescigno et al.
CLINICAL CANCER RESEARCH (2021)
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors
Emmanuel S. Antonarakis et al.
JCO PRECISION ONCOLOGY (2020)
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
David A. Quigley et al.
CELL (2018)
MSH2 Loss in Primary Prostate Cancer
Liana B. Guedes et al.
CLINICAL CANCER RESEARCH (2017)
Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
Ilirjana Bajrami et al.
CANCER RESEARCH (2014)
Share Paper
